Island Pharmaceuticals (ASX: $ILA) announces positive ISLA-101 study results

Island Pharmaceuticals Ltd (ASX: $ILA) has announced highly encouraging pharmacokinetics (PK) data from its ISLA-101 Single Ascending Dose study. The study, involving 24 subjects, revealed positive pharmacokinetic data and reconfirmed strong safety and tolerability data for ISLA-101, a drug candidate being repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases.

Executive Commentary on ISLA-101 Study Results

Island Pharmaceuticals' CEO, Dr David Foster, expressed his confidence in ISLA-101, stating, 'This new pharmacokinetic data reinforces our strong confidence in ISLA-101. The data has shown us that even following a single dose, we are achieving blood concentrations that have previously been shown to be effective against dengue fever infections.' Dr Foster also highlighted the significance of the study in preparing for the Phase 2 clinical trial and the potential impact on dosing regimens.

Summary of ISLA-101 Study Results and Outlook

The ISLA-101 Single Ascending Dose study by Island Pharmaceuticals has provided highly positive pharmacokinetic data, reinforcing the company's confidence in the drug's effectiveness against dengue fever infections. The study's outcomes are crucial in establishing appropriate dosing regimens for the planned Phase 2a clinical trial. Island Pharmaceuticals aims to leverage this data to advance its drug repurposing efforts and potentially obtain FDA approval for ISLA-101, which could lead to expedited FDA approval processes or the sale of a Priority Review Voucher (PRV) in the secondary market. The company encourages investors to go paperless and stay updated on further developments through its website.